Fabry Disease
Conditions
Keywords
high risk screening, Chronic kidney disease
Brief summary
Fabry disease is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene. It is characterized by severe multi-systemic involvement that leads to major organ failure and premature death in affected men and in some women. The α-Gal A deficiency results in progressive accumulation of un-degraded glycosphingolipids, predominantly globotriaosylceramide (Gb3), within cell lysosomes throughout the body. In patients at the second or third decade, progressive proteinuria, decline in glomerular filtration rate (GFR), and tubular damage occur usually, and renal failure develops in the fourth decade. Life-threatening renal, cardiac, and cerebrovascular diseases are added in later decades. In addition to that, Fabry disease patient will eventually face end-stage renal disease (ESRD) which was the most common cause of death in Fabry patients before the development of dialysis and renal transplantation. Thus it is critical to identify Fabry patient as early as possible, before reaching the stage of ESRD. Additionally, early intervention of enzyme replacement therapy for Fabry Disease patient which will help the patient to preserve a better renal function and benefit from treatment outcome. Apart from that today there is only one study published from Turkey for Fabry disease screening in CKD patient where they have screened 1453 and found that the overall prevalence of Fabry disease in CKD patient was found to be 0.2% , 3/1453 (in which 0.4% in 656 male, 0.0% in 783 female). However, there was no information available within the Asia region thereby a very low Fabry disease awareness and diagnostic awareness among nephrologist in Taiwan. Therefore in the present study the investigators are aiming to investigate the prevalence of Fabry disease in the CKD population (CKD stage 1 \ 5) by conducting the first and largest high risk screening prevalence study among 2,000 CKD patients over 3 years in Taiwan and the investigators hope by doing such a pilot study our data would contribute to a new paradigm of Fabry disease diagnosis in the Asia region.
Interventions
DIAGNOSTIC_TESTPlasma α-Gal A activity; Plasma Lyso-GB3; GLA genetic sequencing.
Screening Visit 1: 1. Male patient will first screened by enzymatic assay (Cutoff: 1.3 μM /hr) 2. Female patient will first screened by lyso-GB3 (Cutoff: \> 5ng/ml) Screening Visit 2: If both male and female who has deficient enzymatic level (Cutoff: 1.3 μM /hr) or lyso-GB3 level (Cutoff: \> 5ng/ml) respectively, those patients will be confirmed whether they have carried Fabry Disease causing mutation by whom GLA genetic sequencing.
Sponsors
Chang Gung Memorial Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient age ≥ 18 y/o (No age limit due to cardiac variant Fabry IVS4 in Taiwan symptom of onset could be beyond 60 y/o) * Patient with confirmed chronic kidney disease (CKD 1\ 5) diagnosis whose urine protein/creatinine (UPCR) is 150mg/g or above, or urine albumin/creatinine (ACR) is 30mg/g or above. * Patient who are willing to sign inform consent form
Exclusion criteria
* Patient who are unwilling to sign inform consent form * Patient who received confirmed diagnosis of Fabry Disease * Patient with known etiology of renal failure diagnosed with renal biopsy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Positive screening rate of Fabry Disease patient among CKD population | 48 months | Identify the prevalence rate of Fabry disease in patients with CKD including dialysis in Taiwan. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of gene mutation pattern of Fabry patients with CKD in Taiwan | 48 months | Identify what gene mutation(s) is(are) significant associated with Fabry patients with CKD in Taiwan |
Countries
Taiwan
Contacts
Primary ContactChien-Hsing Wu, MD
Backup ContactYichun Lin
Outcome results
None listed